About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Trp53tm2Tyj
targeted mutation 2, Tyler Jacks
MGI:3039263
Summary 16 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Trp53tm2Tyj/Trp53tm2Tyj involves: 129S4/SvJae MGI:5293780
cn2
Trp53tm1Brn/Trp53tm2Tyj involves: 129P2/OlaHsd * 129S4/SvJae MGI:5293783
cn3
Trp53tm1Brn/Trp53tm1Brn
Trp53tm2Tyj/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae MGI:5293787
cn4
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129P2/OlaHsd * 129S4/SvJae MGI:5510703
cn5
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae MGI:3716966
cn6
Mettm1Sst/Mettm1Sst
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae MGI:5293786
cn7
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd MGI:5704370
cn8
Dicer1tm1Tara/Dicer1tm1Tara
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd MGI:5704374
cn9
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd MGI:5704372
cn10
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N MGI:5617494
cn11
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N MGI:5617496
cn12
Brca2tm1Brn/Brca2tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N MGI:5617497
cn13
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae MGI:3716965
cn14
Amhr2tm3(cre)Bhr/Amhr2+
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae * 129S7/SvEvBrd MGI:5704376
cn15
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
Trp53tm2Tyj/Trp53tm2Tyj
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL MGI:5528297
cn16
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N MGI:4941336


Genotype
MGI:5293780
cn1
Allelic
Composition
Trp53tm2Tyj/Trp53tm2Tyj
Genetic
Background
involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit very limited proliferation potential and undergo senescence sooner than control cells that become immortalized




Genotype
MGI:5293783
cn2
Allelic
Composition
Trp53tm1Brn/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit increased invasion compared with control cells that is not as severe as in similarly treated cells from Trp53tm1Brn homozygotes




Genotype
MGI:5293787
cn3
Allelic
Composition
Trp53tm1Brn/Trp53tm1Brn
Trp53tm2Tyj/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit increased invasion compared with control cells that is not as severe as in similarly treated cells from Trp53tm1Brn homozygotes




Genotype
MGI:5510703
cn4
Allelic
Composition
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (4 available); any Kras mutation (32 available)
Ptf1atm1(cre)Hnak mutation (0 available); any Ptf1a mutation (10 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• however, treatment with a potent and selective oral pan class I PI3K inhibitor (GDC 0941) blocks tumor growth

neoplasm
• however, treatment with a potent and selective oral pan class I PI3K inhibitor (GDC 0941) blocks tumor growth




Genotype
MGI:3716966
cn5
Allelic
Composition
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (4 available); any Kras mutation (32 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes

neoplasm
• at 19 weeks following cre-adenovirus treatment, sinonasal adenocarninomas develop in 64% of mice
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes




Genotype
MGI:5293786
cn6
Allelic
Composition
Mettm1Sst/Mettm1Sst
Trp53tm1Brn/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mettm1Sst mutation (1 available); any Met mutation (28 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
N
• ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit reduced invasion compared with similarly treated cells from Trp53tm1Brn/Trp53tm2Tyj mice




Genotype
MGI:5704370
cn7
Allelic
Composition
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Amhr2tm3(cre)Bhr mutation (1 available); any Amhr2 mutation (14 available)
Dicer1tm1Tara mutation (1 available); any Dicer1 mutation (52 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (41 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• ovary has on overgrowth of tumors composed of cells showing nuclear pleiomprhism, irregular chromatin distribution, macronucleoli, increased mitotic activity and widespread apoptosis resembling high-grade human serous ovarian cancer

endocrine/exocrine glands
• ovary has on overgrowth of tumors composed of cells showing nuclear pleiomprhism, irregular chromatin distribution, macronucleoli, increased mitotic activity and widespread apoptosis resembling high-grade human serous ovarian cancer

neoplasm
• mice show widespread peritoneal metastases, including omentum and diaphragm
• the overall metastatic tumor burden in fallopian tube-removed mice is less extensive than that of intact mice
• mice develop massive high-grade serous carcinomas that always arise from the fallopian tube
• however when fallopian tubes are removed, mice develop high-grade serous carcinomas originating from the ovary, indicating that the ovary can be a source of carcinomas but is less dominant in tumorigenesis than the fallopian tube
• ovary has on overgrowth of tumors composed of cells showing nuclear pleiomprhism, irregular chromatin distribution, macronucleoli, increased mitotic activity and widespread apoptosis resembling high-grade human serous ovarian cancer

mortality/aging
• premature death starting around 6 months of age with all mice dying by around 8 months of age
• fallopian tube-removed mice die at around 8-14 months of age after inducing ascites

homeostasis/metabolism

Mouse Models of Human Disease
OMIM ID Ref(s)
Ovarian Cancer 167000 J:222579




Genotype
MGI:5704374
cn8
Allelic
Composition
Dicer1tm1Tara/Dicer1tm1Tara
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Amhr2tm3(cre)Bhr mutation (1 available); any Amhr2 mutation (14 available)
Dicer1tm1Tara mutation (1 available); any Dicer1 mutation (52 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• mice do not develop ovarian or fallopian tube high grade serous carcinomas




Genotype
MGI:5704372
cn9
Allelic
Composition
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Amhr2tm3(cre)Bhr mutation (1 available); any Amhr2 mutation (14 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (41 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• 70% of mice develop granulosa-cell tumors in the ovary
• 30% of mice develop high-grade serous carcinoma originating in the ovary
• however, mice do not develop serous carcinomas originating from the fallopian tube

endocrine/exocrine glands
• 70% of mice develop granulosa-cell tumors in the ovary
• 30% of mice develop high-grade serous carcinoma originating in the ovary
• however, mice do not develop serous carcinomas originating from the fallopian tube

neoplasm
• 70% of mice develop granulosa-cell tumors in the ovary
• 30% of mice develop high-grade serous carcinoma originating in the ovary
• however, mice do not develop serous carcinomas originating from the fallopian tube
• serous carcinoma spreads throughout the peritoneal cavity, to the omentum and across the peritoneal membrane, including the mesentery and diaphragm

mortality/aging
• median survival is 11.2 months of age, with mice dying between 7.6 and 15.3 months of age

homeostasis/metabolism

Mouse Models of Human Disease
OMIM ID Ref(s)
Ovarian Cancer 167000 J:222579




Genotype
MGI:5617494
cn10
Allelic
Composition
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

reproductive system
• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

neoplasm
• 72% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease
OMIM ID Ref(s)
Ovarian Cancer 167000 J:189304




Genotype
MGI:5617496
cn11
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (75 available)
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs

neoplasm
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs
• distant metastases are seen in the pleura of 87.5%, in the lung of 83% and in the liver of 46% of mutants intrabursally injected with Ad-cre that develop stage IV disease
• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma

reproductive system
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs
• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma
• oviduct lesions are characterized by a glandular/acinar histology

homeostasis/metabolism
• ovaries in intrabursally Ad-cre injected mice show hemorrhagic or serous ascites

Mouse Models of Human Disease
OMIM ID Ref(s)
Ovarian Cancer 167000 J:189304




Genotype
MGI:5617497
cn12
Allelic
Composition
Brca2tm1Brn/Brca2tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca2tm1Brn mutation (2 available); any Brca2 mutation (62 available)
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (146 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

endocrine/exocrine glands
• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

neoplasm
• 68% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease
OMIM ID Ref(s)
Ovarian Cancer 167000 J:189304




Genotype
MGI:3716965
cn13
Allelic
Composition
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Genetic
Background
involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (4 available); any Kras mutation (32 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes (J:103407)
• following cre-adenovirus treatment, tumors occupy 27% of lung space (J:103407)
• mice treated with intratracheal delivery of cre-expressing adenovirus develop lung cancer (J:191425)
• mice infected with higher doses of cre expressing adenovirus present with clinical signs of lung cancer by 15 weeks of treatment while lower dosed animals show signs of disease around 37 weeks (J:191425)
• a subset of tumors from mice treated with intratracheal delivery of cre-expressing adenovirus show loss of heterozygosity of Trp53 (J:191425)
• treatment of mice treated with intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus almost completely abrogates tumor formation (J:191425)
• treatment of mice that have already formed lung tumors following intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus prevents further progression of tumors (J:191425)
• mice treated with intratracheal delivery of cre-expressing adenovirus show evidence that high-grade adenocarcinomas acquire metastatic characteristics of non-small cell lung cancer
• tumors of mice treated with intratracheal delivery of cre-expressing adenovirus are adenocarcinomas and some evidence that high-grade adenocarcinomas acquire metastatic characteristics

immune system
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit large lungs filled with tumors and inflammation
• the inflammation that develops in the lungs of mice treated with intratracheal delivery of cre-expressing adenovirus occurs after initial nodules develop

behavior/neurological
• mice treated with intratracheal delivery of cre-expressing adenovirus develop a hunched posture in the most severe cases

growth/size/body
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit a decline in weight

respiratory system
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit large lungs filled with tumors and inflammation
• the inflammation that develops in the lungs of mice treated with intratracheal delivery of cre-expressing adenovirus occurs after initial nodules develop
• following cre-adenovirus treatment, all mice develop primary lung tumors that are similar to those found in Krastm4Tyj Trp53tm1Brn heterozygotes (J:103407)
• following cre-adenovirus treatment, tumors occupy 27% of lung space (J:103407)
• mice treated with intratracheal delivery of cre-expressing adenovirus develop lung cancer (J:191425)
• mice infected with higher doses of cre expressing adenovirus present with clinical signs of lung cancer by 15 weeks of treatment while lower dosed animals show signs of disease around 37 weeks (J:191425)
• a subset of tumors from mice treated with intratracheal delivery of cre-expressing adenovirus show loss of heterozygosity of Trp53 (J:191425)
• treatment of mice treated with intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus almost completely abrogates tumor formation (J:191425)
• treatment of mice that have already formed lung tumors following intratracheal delivery of cre-expressing adenovirus with an miR-34 expressing lentilvirus prevents further progression of tumors (J:191425)
• mice treated with intratracheal delivery of cre-expressing adenovirus show evidence that high-grade adenocarcinomas acquire metastatic characteristics of non-small cell lung cancer
• tumors of mice treated with intratracheal delivery of cre-expressing adenovirus are adenocarcinomas and some evidence that high-grade adenocarcinomas acquire metastatic characteristics
• mice treated with intratracheal delivery of cre-expressing adenovirus exhibit labored breathing

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:191425




Genotype
MGI:5704376
cn14
Allelic
Composition
Amhr2tm3(cre)Bhr/Amhr2+
Trp53tm2Tyj/Trp53+
Genetic
Background
involves: 129S4/SvJae * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Amhr2tm3(cre)Bhr mutation (1 available); any Amhr2 mutation (14 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• mice do not develop ovarian or fallopian tube high grade serous carcinomas




Genotype
MGI:5528297
cn15
Allelic
Composition
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
Trp53tm2Tyj/Trp53tm2Tyj
Genetic
Background
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1.1Brd mutation (0 available); any Braf mutation (32 available)
Tg(Vil1-cre)997Gum mutation (2 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• invasiveness of cancers considerably increased
• 56% of mice at 10-20 months
• 25% of cancerous mice have metastases




Genotype
MGI:4941336
cn16
Allelic
Composition
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (4 available); any Kras mutation (32 available)
Tg(Pdx1-cre)6Tuv mutation (1 available)
Trp53tm2Tyj mutation (2 available); any Trp53 mutation (146 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• all but one mouse, develop large, firm, fibrotic head of the pancreas tumors
• metastatic foci spread to the surface of the liver, lungs, diaphragm, and adrenals with occasional metastasis to the peripancreatic, mesenteric, and retroperitoneal lymph nodes
• mice exhibit the full spectrum of preinvasive lesions
• some tumors are minor, poorly differentiated, or undifferentiated with anaplastic or sarcomatoid features

mortality/aging

neoplasm
• all but one mouse, develop large, firm, fibrotic head of the pancreas tumors
• metastatic foci spread to the surface of the liver, lungs, diaphragm, and adrenals with occasional metastasis to the peripancreatic, mesenteric, and retroperitoneal lymph nodes
• mice exhibit the full spectrum of preinvasive lesions
• some tumors are minor, poorly differentiated, or undifferentiated with anaplastic or sarcomatoid features
• some mice exhibit esophageal papillomas and hyperplasias or papillomatosis of the biliary tree unlike control mice

liver/biliary system

homeostasis/metabolism
• hemorrhagic

cellular
• in tumor cells

growth/size/body

digestive/alimentary system
• mice frequently exhibit small bowel obstructions unlike control mice

Mouse Models of Human Disease
OMIM ID Ref(s)
Pancreatic Cancer 260350 J:98936





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/29/2016
MGI 6.06
The Jackson Laboratory